Ionis Pharmaceuticals (IONS) Total Non-Current Liabilities (2010 - 2026)

Ionis Pharmaceuticals' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $2.9 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 28.43% year-over-year to $2.9 billion; the TTM figure through Mar 2026 stood at $2.9 billion (up 28.43% YoY), while the FY2025 annual figure was $3.0 billion, up 27.22% from the prior year.
• Total Non-Current Liabilities was $2.9 billion for Q1 2026 at Ionis Pharmaceuticals, down from $3.0 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $3.0 billion in Q4 2025 to a low of $1.9 billion in Q1 2023.
• Historically, Total Non-Current Liabilities has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities slipped 3.83% in 2025, then increased 28.43% in 2026.
• A 5-year view of Total Non-Current Liabilities shows it stood at $2.0 billion in 2022, then increased by 6.56% to $2.1 billion in 2023, then increased by 13.1% to $2.4 billion in 2024, then gained by 27.22% to $3.0 billion in 2025, then retreated by 2.54% to $2.9 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $2.9 billion (Q1 2026), $3.0 billion (Q4 2025), and $2.4 billion (Q3 2025), per Business Quant data.